Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting
MILLBRAE, Calif. & CHICAGO--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with traditional biology research to accelerate drug discovery, today announced that new data from its oncology programs will be presented in collaboration with independent investigators at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 – June 3, 2025, in Chicago, Illinois. Alongside these presentations, Eikon will also share additional milestone updates across its broad and diverse research and development pipeline.
We are pleased to share these advances with the oncology community at ASCO as we work to deliver new medicines to address serious illnesses.
Share
'We are encouraged by the progress we are seeing across our clinical-stage oncology programs, which reflect both the potential of these candidates and the capabilities of the fully integrated development organization that we are building at Eikon,' said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer of Eikon Therapeutics. 'Our team brings deep experience in advancing therapies through clinical studies and regulatory review, and we are pleased to see that capability reflected in the progress of our lead programs. At the same time, we continue to advance a pipeline of internally derived candidates, informed by the insights of our novel technology platform and Single Molecule Tracking (SMT) system. We look forward to positioning our results in the context of what has been achieved by the broader ASCO community.'
ASCO 2025 Presentations
The following posters will spotlight new first-in-human and combination data from Eikon's two most advanced clinical programs.
EIK1001-006 (Abstract: TPS9604)
Title: TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma
Date and time: June 1, 2025, from 9:00 AM – 12:00 PM CDT
Presenter: Jason J. Luke, M.D., UPMC, Hillman Cancer Center
EIK1003-001 (Abstract: 3122)
Title: Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors
Date and time: June 2, 2025, from 1:30 PM – 4:30 PM CDT
Presenter: Guru P. Sonpavde, M.D., AdventHealth Cancer Institute
Recent Program Milestones
In addition to its presentations at ASCO, Eikon will be discussing recent program milestones including:
EIK1001-006 (TeLuRide-006, NCT06697301): The first patient has been enrolled in the TeLuRide-006 trial, which is investigating the potential role of EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 that has been observed to exhibit clinical activity as a monotherapy and in combination with anti-PD-(L)1 agents across multiple solid tumor types in Phase 1 trials, as an addition to standard of care pembrolizumab (KEYTRUDA ®) for the treatment of patients with advanced metastatic melanoma. TeLuRide-006 is a global, multicenter, randomized, double-blind, active comparator-controlled, adaptive Phase 2/3 trial to evaluate the safety and efficacy of EIK1001 and pembrolizumab versus placebo and pembrolizumab as first-line therapy in participants with advanced melanoma. The trial includes dose optimization and dose expansion parts. Eikon has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). Under the terms of the Agreement, Merck will provide pembrolizumab to Eikon. Eikon will be the sponsor of the Phase 2/3 clinical trial.
EIK1001-005 (TeLuRide-005, NCT06246110): Enrollment continues as planned in this Phase 2 trial testing EIK1001 with pembrolizumab and chemotherapy in patients with squamous and nonsquamous non-small cell lung cancer. The trial's primary objective is to evaluate the safety and tolerability of EIK1001. Eikon also hopes to learn whether the immunomodulatory mechanism of EIK1001 might improve standard therapy in this hard-to-treat setting.
EIK1003-001 (NCT06253130): Enrollment is proceeding in the trial of EIK1003, a highly selective PARP1 inhibitor, in adults with advanced solid tumors. Initial pharmacokinetic, safety, tolerability, and early efficacy findings from the monotherapy dose-escalation cohort will be reported in an ASCO 2025 poster (Abstract: 3122).
EIK1004-001 (NCT06907043): The first patient has been dosed in a Phase 1/2 trial of EIK1004, a CNS-penetrant selective PARP1 inhibitor. This trial is assessing safety, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity in patients with advanced solid tumors, including those with brain metastases.
'The steady progress we are making as evidenced by the first safety and efficacy data from EIK1003, the initiation of our adaptive melanoma study with EIK1001, and the recent first-patient dosing of the CNS-penetrant selective PARP1 inhibitor EIK1004, underscores the momentum Eikon's clinical team is building across our oncology portfolio,' said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon Therapeutics. 'Their deep experience in oncology is translating into real world progress, and we are pleased to share these advances with the oncology community at ASCO as we work to deliver new medicines to address serious illnesses.'
Eikon at AACR 2025
The Eikon Therapeutics team also recently presented program data at the 2025 American Association for Cancer Research (AACR) conference. These presentations included:
EIK1004-001 (Abstract#5719): Identification of EIK1004: A CNS-penetrant, potent and selective PARP1 inhibitor poised for testing in patients with HRD mutant tumors. The poster presented data on methodologies to optimize early lead PARP1 inhibitors with novel structures for selectivity and CNS penetration leading to discovery of EIK1004.
EIK1003-001 (Abstract # CT197): A first-in-human, Phase 1/2 dose escalation, dose-optimization, and dose-expansion trial of PARP1-selective inhibitor EIK1003 in patients with advanced solid tumors.
The Eikon team will also welcome attendees at ASCO Booth #14143 to discuss these and its other pipeline programs.
About Eikon Therapeutics
Eikon Therapeutics is dedicated to advancing breakthrough therapies through the purposeful integration of science and engineering. Our research tools, including our proprietary SMT system, leverage Nobel Prize-winning super-resolution microscopy, bespoke automation, advanced data science, and software engineering to visualize and measure the real-time movement of proteins in living cells, with the goal of developing important innovative medicines to address serious unmet medical needs. Eikon operates from its facilities in California, New Jersey, and New York, and can be found online at www.EikonTx.com or LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis
BLACK RIVER FALLS, Wis., June 11, 2025--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the "Company"), a leading civil, building and specialty construction company, announced today that its subsidiary, Lunda Construction Company, has been awarded a contract by the Minnesota Department of Transportation valued at approximately $67.2 million for the I-94 and I-394 Interchange Project in Minneapolis. The scope of work includes repairing 34 bridges and ramps along I-394 and I-94 between downtown Minneapolis and Highway 100. The project also includes maintenance work on the Dunwoody Boulevard ramp, replacing the deck for the Penn Avenue bridge that crosses over I-394, and other improvements along I-394 between downtown Minneapolis and Highway 100. Work is expected to begin in July 2025 with substantial completion anticipated in the summer of 2027. The contract value has been added to the Company's backlog in the second quarter of 2025. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection. View source version on Contacts Tutor Perini CorporationJorge Casado, 818-362-8391Senior Vice President, Investor Relations and Corporate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
32 minutes ago
- Business Wire
Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis
BLACK RIVER FALLS, Wis.--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the 'Company'), a leading civil, building and specialty construction company, announced today that its subsidiary, Lunda Construction Company, has been awarded a contract by the Minnesota Department of Transportation valued at approximately $67.2 million for the I-94 and I-394 Interchange Project in Minneapolis. The scope of work includes repairing 34 bridges and ramps along I-394 and I-94 between downtown Minneapolis and Highway 100. The project also includes maintenance work on the Dunwoody Boulevard ramp, replacing the deck for the Penn Avenue bridge that crosses over I-394, and other improvements along I-394 between downtown Minneapolis and Highway 100. Work is expected to begin in July 2025 with substantial completion anticipated in the summer of 2027. The contract value has been added to the Company's backlog in the second quarter of 2025. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection.
Business Wire
an hour ago
- Business Wire
Hagens Berman Responds to Appeals to NCAA College Athlete Name, Image and Likeness Settlement
OAKLAND, Calif.--(BUSINESS WIRE)--Following the federal court's final approval to a historic $20 billion plus settlement with the NCAA allowing payments and benefits to college athletes for the use of their name, image and likeness (NIL), Hagens Berman responded to the first appeal. 'If these lawyers believe that a Title IX case will succeed, they should bring it and not hijack payments to college athletes that could be lifechanging.' To address questions from NCAA athletes about the impact of the appeal, Hagens Berman issued the following statement: 'Attorneys John Clune and Ashlyn Hare of Hutchinson Black and Cook LLC and Rebecca Peterson-Fisher of Katz Banks Kumin LLP have filed a notice of their intent to appeal the historic NCAA settlement approved June 6, 2025, by Judge Claudia Wilken. 'This appeal will block payments to hundreds of thousands of athletes, delaying payments by a minimum of several months to potentially a year or more. These attorneys are pursuing an appeal based on a Title IX issue that Judge Wilken already disposed of correctly, quickly and multiple times. 'Judge Wilken noted that these attorneys cited 'no authority that Title IX applies to damages awards distributions or that damages distributions made by a claims administrator are subject to Title IX.'' 'This is an antitrust case about competition, it is not a Title IX case, and now hundreds of thousands of athletes will have to wait to recover for past wrongs that were addressed in this lawsuit in order for these attorneys to take on this unrelated issue,' added Hagens Berman co-founder and managing partner, Steve Berman, who serves as court-appointed co-lead counsel. 'If these lawyers believe that a Title IX case will succeed, they should bring it and not hijack payments to college athletes that could be lifechanging.' Straight from the Bench In Judge Wilken's June 6, 2025, opinion on the order granting final approval to the settlement, the court clearly states that it overrules objections, noting, 'There is nothing in the SA [settlement agreement] that would prevent or prohibit schools from distributing benefits and compensation pursuant to the Injunctive Relief Settlement in a manner that complies with Title IX.' Berman added, 'Judge Wilken had made that same ruling earlier in the case, theoretically allowing objectors ample time to find authority to back up their objection, and they failed. It's a shame given this utter failure they will be holding up payments to athletes. I say shame on them.' Hagens Berman represents a class of nearly 400,000 college athletes in the lawsuit in which the total value under the new revenue-sharing model is expected to exceed $20 billion over the next 10 years. The settlement resolves three pending antitrust lawsuits, House v. NCAA, Hubbard v. NCAA, and Carter v. NCAA. Class members in the three affected cases may find out more about the claim process by visiting the settlement website at . Hagens Berman is a global plaintiffs' rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm's determination has earned it numerous national accolades, awards and titles of 'Most Feared Plaintiff's Firm,' MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.
